The Food and Drug Administration (FDA) approved the first new medication to treat ADHD in children in over a decade last week.
According to the AP, Qelbree, unlike other ADHD drugs, is not a stimulant. That makes it less addictive and less likely to be abused than other medicines that contain either amphetamine or methylphenidate. Qelbree, also known as viloxazine, comes with a warning that it may cause suicidal thoughts and behavior, which was observed in less than 1 percent of volunteers in studies.
The drug's developer, Supernus Pharmaceuticals of Rockville, Md., has not disclosed what the price of Qelbree will be, though it will likely be more expensive than generic ADHD medications.